OUR SOLUTION FOR CLINICAL TRIALS ON AMYOTROPHIC LATERAL SCLEROSIS (ALS)

With no cure currently available for ALS, only two FDA-approved drugs for ALS treatment on the market, and a rising incidence rate of this rare disease, the need for a new treatment and cure for ALS is high. The new scientific advances coming through from the laboratory need clinical trials that are conducted efficiently and at the right research centers.

Julius clinical provides three key success criteria for conducting clinical trials in ALS:

  1. Scientific excellence through our close working relationship with a global Key Opinion Leader in the ALS field, Prof. L. van den Berg
  2. Operational in-house expertise and a track record in running pivotal global ALS clinical trials
  3. Partnerships with the leading European ALS trial network, TRICALS, and key research centers